2-(1-adamantyl)-6-methoxy-8-nitroquinoline | 655250-12-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-(1-adamantyl)-6-methoxy-8-nitroquinoline
• 英文别名: 2-adamantyl-6-methoxy-8-nitroquinoline
• CAS: 655250-12-7
• 化学式: C₂₀H₂₂N₂O₃
• 分子量: 338.406
• InChiKey: ZHUXPJGPJREIDY-UHFFFAOYSA-N

物化性质

• 沸点：
  512.9±45.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(1-adamantyl)-6-methoxy-8-nitroquinoline 在 镍 氢气 作用下， 以 乙醇 为溶剂， 反应 0.75h， 生成 2-(1-adamantyl)-6-methoxy-8-quinolinamine
  参考文献：
  名称：

  Discovery of a Bulky 2-tert-Butyl Group Containing Primaquine Analogue That Exhibits Potent Blood-Schizontocidal Antimalarial Activities and Complete Elimination of Methemoglobin Toxicity

  摘要：

  To eliminate an unwarranted metabolic pathway of the quinoline ring, a set of two compounds, where C-2 position of the antimalarial drug primaquine is blocked by metabolically stable bulky alkyl group are synthesized. Compound 2 [R = C(CH3)(3)] of the series has produced excellent antimalarial efficacy against P. berghei and highly virulent multidrug-resistant P. yoelii nigeriensis strain in vivo. Compound 2 was also evaluated for methemoglobin (MetHb) toxicity. This study describes the discovery of a highly potent blood-schizontocidal antimalarial analogue 2, completely devoid of MetHb toxicity.

  DOI：

  10.1021/jm0304562
• 作为产物：
  描述：

  6-甲氧基-8-硝基喹啉 、 1-金刚烷甲酸 在 silver nitrate ammonium peroxydisulfate 、 硫酸 、 氨 作用下， 以 水 、 乙腈 为溶剂， 反应 0.33h， 以70%的产率得到2-(1-adamantyl)-6-methoxy-8-nitroquinoline
  参考文献：
  名称：

  Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents

  摘要：

  本发明涉及新型8-氨基喹啉类似物在治疗和预防疟疾方面的开发，所述化合物对人类疟原虫的血期及组织期具有广谱活性，使得这些化合物在治疗和预防由药物敏感和多药耐药菌株引起的疟疾方面极具吸引力。同时，预期将这些化合物开发为理想的抗疟药物可能会导致单一药物疗法既能抑制又能根治疟疾感染。

  公开号：

  US20040192724A1

文献信息

• Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents
  申请人：——

  公开号：US20040192724A1

  公开（公告）日：2004-09-30

  The present invention is concerned with the development of novel 8-aminoquinoline analogs in the treatment and prevention of malaria and the said compound has broad spectrum of activity against the blood as well as tissue stages of the human malaria parasites makes these compounds very attractive in the cure and prevention of malaria caused by drug-sensitive and multidrug resistant strains and also it is expected that development of these compounds as ideal antimalarial agents may lead to suppression as well as radical cure of the malaria infection with single drug therapy.

  本发明涉及新型8-氨基喹啉类似物在治疗和预防疟疾方面的开发，所述化合物对人类疟原虫的血期及组织期具有广谱活性，使得这些化合物在治疗和预防由药物敏感和多药耐药菌株引起的疟疾方面极具吸引力。同时，预期将这些化合物开发为理想的抗疟药物可能会导致单一药物疗法既能抑制又能根治疟疾感染。
• RING-SUBSTITUTED 8-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIAL AGENTS
  申请人：COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

  公开号：EP1606263A1

  公开（公告）日：2005-12-21
• Methods and compositions for the treatment of neurodegenerative disorders
  申请人：Jin Xiaowei

  公开号：US20080044390A1

  公开（公告）日：2008-02-21

  The present invention features compositions, kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease.
• US6979740B2
  申请人：——

  公开号：US6979740B2

  公开（公告）日：2005-12-27
• [EN] RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS<br/>[FR] DERIVES DE 8-AMINOQUINOLINE A CYCLE SUBSTITUE UTILES COMME AGENTS ANTI-PALUDEENS
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2004085402A1

  公开（公告）日：2004-10-07

  The present invention is concerned with the development of novel 8-aminoquinoline analogs according to formula (1) with the definitions of R, R<1>, R<2> and R<3> in the description in the treatment and prevention of malaria. The said compounds have broad, spectrum of activity against the blood as well as tissue stages of the human malaria parasites makes these compounds very attractive in the cure and prevention of malaria caused by drug-sensitive and multidrug resistant strains. It is expected that development of these compounds as ideal antimalarial agents may lead to suppression as well as radical cure of the malaria infection with single drug therapy.